Gilead Sciences ( GILD ) Q2 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Arcellx, Inc. ( ACLX ) Reports Q2 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of +8.74% and -54.93%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Arcellx ( ACLX ) Q2 Revenue Drops 72%
Arcellx ( NASDAQ:ACLX ) , a biotechnology company developing cell therapies for blood cancers and autoimmune diseases, reported its second quarter 2025 results on August 7, 2025. The most notable update centered on a sharp revenue miss and a wider net loss, even as key clinical milestones ...
FDA Eases Access To Life-Saving Gene Therapies For Blood Cancers - Johnson & Johnson ( NYSE:JNJ ) , Novartis ( NYSE:NVS ) , Gilead Sciences ( NASDAQ:GILD ) , Bristol-Myers Squibb ( NYSE:BMY )
FDA eliminated REMS for six approved CAR-T therapies. Patients no longer need to stay near treatment site for two weeks or avoid driving post-therapy. Market-moving news hits Benzinga Pro first-get a 30-minute edge and save 60% this 4th of July. The U.S.
Dycom Industries Posts Upbeat Earnings, Joins WeRide, Keysight Technologies And Other Big Stocks Moving Higher On Wednesday - Arcellx ( NASDAQ:ACLX ) , Akso Health ( NASDAQ:AHG )
U.S. stocks were lower, with the Dow Jones index falling around 300 points on Wednesday. Shares of Dycom Industries, Inc. DY rose sharply during Wednesday's session after the company reported better-than-expected first-quarter financial results, issued second-quarter sales guidance above ...
Arcellx, Inc. ( ACLX ) Reports Q1 Loss, Lags Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of -34.52% and 55.30%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Crescent Biopharma Appoints David Lubner to Board of Directors - GlycoMimetics ( NASDAQ:GLYC )
Industry Veteran Brings 30 Years of Experience in Finance, Strategy and Operations
Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday - Arcellx ( NASDAQ:ACLX ) , Allegiant Travel ( NASDAQ:ALGT )
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Wednesday. Shares of Cognyte Software Ltd. CGNT rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results.
The International Myeloma Foundation Announces 2nd Annual Iceland Cycling Expedition, to be Held from August 27 - September 2
STUDIO CITY, Calif., March 13, 2025 ( GLOBE NEWSWIRE ) -- The International Myeloma Foundation ( IMF ) is excited to announce that the 2nd annual Iceland Cycling Expedition ( ICE ) -a 6-night/7-day endurance fundraiser biking expedition -will take place from August 27 - September 2, 2025, in ...
Arcellx, Inc. ( ACLX ) Reports Q4 Loss, Lags Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of -38.10% and 44.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention - Gilead Sciences ( NASDAQ:GILD )
Gilead's Q4 revenue rose 6% to $7.57 billion, surpassing the $7.14 billion consensus. Gilead raised its dividend by 2.6% to $0.79 per share. Get real-time earnings alerts before the market moves and access expert analysis that uncovers hidden opportunities in the post-earnings chaos.
Gilead Sciences ( GILD ) Q4 2024 Earnings Call Transcript
GILD earnings call for the period ending December 31, 2024.
Adaptive Biotechnologies ( ADPT ) Soars 18.0%: Is Further Upside Left in the Stock?
Adaptive Biotechnologies (ADPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
( ACLX ) - Analyzing Arcellx's Short Interest - Arcellx ( NASDAQ:ACLX )
Arcellx's ACLX short percent of float has risen 6.49% since its last report. The company recently reported that it has 5.81 million shares sold short, which is 12.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.85 days to cover their ...
Primrose Bio to Collaborate with Serum Institute of India to Develop a Novel Multi-Antigen Vaccine
SAN DIEGO, Jan. 10, 2025 /PRNewswire/ -- Primrose Bio, Inc. ( "Primrose" ) , a company with proprietary manufacturing technologies for human therapeutics, and Serum Institute of India Pvt.
Guardant Health ( GH ) Soars 6.3%: Is Further Upside Left in the Stock?
Guardant Health (GH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
5 Biotech Breakthrough Stocks to Watch in 2025
It is a good idea to keep an eye on five biotech breakthrough stocks, MDMD, BEAM, ACLX, OCGN and INSM, as they may give great returns in the next 2-3 years ...
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients - Arcellx ( NASDAQ:ACLX )
On Sunday, Arcellx, Inc. ACLX revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel ( anito-cel ) in patients with relapsed or refractory multiple myeloma ( RRMM ) . The data will be presented at the American Society of Hematology ( ASH ) Annual Meeting ...
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. ( ACLX ) is a Great Choice
Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Arcellx ( ACLX ) Outperforming Other Medical Stocks This Year?
Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year.
Arcellx, Inc. ( ACLX ) Reports Q3 Loss, Lags Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of 11.11% and 26.06%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Moderna ( MRNA ) Q3 Earnings and Revenues Surpass Estimates
Moderna (MRNA) delivered earnings and revenue surprises of 101.59% and 47.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcellx ( ACLX ) Stock Jumps 6.7%: Will It Continue to Soar?
Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Gilead Sciences ( GILD ) Q3 2024 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2024.
Lululemon To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Wednesday - Lululemon Athletica ( NASDAQ:LULU )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham cut Apellis Pharmaceuticals, Inc. APLS price target from $85 to $60.
Is Boston Scientific ( BSX ) Stock Outpacing Its Medical Peers This Year?
Here is how Boston Scientific (BSX) and Arcellx, Inc. (ACLX) have performed compared to their sector so far this year.
Gilead Sciences ( GILD ) Q2 2024 Earnings Call Transcript
GILD earnings call for the period ending June 30, 2024.
Arcellx, Inc. ( ACLX ) Reports Q2 Loss, Misses Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of 5.56% and 1.23%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Gilead Sciences ( GILD ) Q2 Earnings and Revenues Beat Estimates
Gilead (GILD) delivered earnings and revenue surprises of 24.84% and 4.71%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Alkermes Lags Q2 Earnings Estimates - Arcellx ( NASDAQ:ACLX ) , Alkermes ( NASDAQ:ALKS )
Alkermes ALKS came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.73 per share. This compares to earnings of $0.55 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -1.37%.
Alkermes ( ALKS ) Lags Q2 Earnings Estimates
Alkermes (ALKS) delivered earnings and revenue surprises of -1.37% and 1.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Molecular Glues Clinical Trial Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The molecular glues pipeline and clinical trial analysis report delivers important insights on ongoing research, clinical strategies, upcoming therapeutics, and commercial analysis.
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation Therapeutics
Primrose Bio Announces Investment from 1315 Capital to Advance Manufacturing Solutions for Next-Generation ... PR ...
Arcellx, Inc. ( ACLX ) Reports Q1 Loss, Tops Revenue Estimates
Arcellx (ACLX) delivered earnings and revenue surprises of 72.55% and 32.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcellx Clears Technical Benchmark, Hitting 80-Plus RS Rating
On Thursday, Arcellx ( ACLX ) received a positive adjustment to its Relative Strength ( RS ) Rating, from 78 to 84. X IBD's unique RS Rating identifies market leadership by using a 1 ( worst ) to 99 ( best ) score that indicates how a stock's price action over the trailing 52 weeks matches up ...
Sarepta Therapeutics ( SRPT ) Q1 Earnings and Revenues Beat Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 763.64% and 10.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Peering Into Arcellx's Recent Short Interest - Arcellx ( NASDAQ:ACLX )
Arcellx's ACLX short percent of float has risen 6.28% since its last report. The company recently reported that it has 3.77 million shares sold short, which is 8.12% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.9 days to cover their ...
How Arcellx ( ACLX ) Stock Stands Out in a Strong Industry
Arcellx (ACLX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Dell, Dun & Bradstreet, Diebold Nixdorf, and More Stocks See Action From Activist Investors
Algonquin Power & UtilitiesStarboard Value increased its stake in the utility company to 62,141,000 shares. Starboard Value did so through the purchase of 150,000 Algonquin Power shares on Feb. 26 at a per share price of $5.73.
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley - Arcellx ( NASDAQ:ACLX )
Morgan Stanley initiates Arcellx Inc ACLX, noting a differentiated CAR-T platform for blood cancer backed by an established CAR-T partner. ddBCMA ( aka anito-cel ) is Arcellx's lead asset, incorporating its patent-protected D-domain as the extracellular binding domain.
Arcellx Analysts Boost Their Forecasts After Q4 Results - Arcellx ( NASDAQ:ACLX )
Arcellx, Inc. ACLX posted financial results for its fourth quarter on Wednesday. The company posted net income of $20.5 million for the quarter ended Dec. 31, 2023, compared to a year-ago net loss of $39.0 million.
Arcellx, Inc. ( ACLX ) Q4 Earnings and Revenues Surpass Estimates
Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of 166.67% and 163.52%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Arcellx Provides Fourth Quarter and Year-End 2023 Financial Results and Business Highlights
-- Presented continued robust long-term responses from Phase 1 expansion trial of anito-cel ( formerly CART-ddBCMA ) in patients with relapsed or refractory multiple myeloma -- -- Ended the quarter with $729.2M, extending cash runway into 2027 --
Gilead Sciences ( GILD ) Q4 2023 Earnings Call Transcript
GILD earnings call for the period ending December 31, 2023.
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 - Arcellx ( NASDAQ:ACLX )
Needham analyst forecasts a positive outlook for Arcellx Inc ACLX in 2024, citing strong potential stemming from the anticipated pivotal interim readout from the iMMagine-1 study, expected in the second half of 2024. This development is poised to bolster filing prospects for the company in 2025.
Gilead ( GILD ) , Compugen Collaborate for Immunotherapy Program
Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
Gilead ( GILD ) Outperforms Industry in 6 Months: What Lies Ahead?
Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session - African Agriculture Hldgs ( NASDAQ:AAGR ) , Achieve Life Sciences ( NASDAQ:ACHV )
Shares of Johnson Controls International plc JCI moved lower during Tuesday's session following weak quarterly results. Johnson Controls reported fourth-quarter FY23 sales growth of 2.7% year-on-year to $6.91 billion ( +2% organically ) , missing the consensus of $7.09 billion.
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say - Arcellx ( NASDAQ:ACLX )
Friday, Arcellx Inc ACLX announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel ( anito-cel ) for relapsed and/or refractory multiple myeloma. The interim anito-cel Phase 1 clinical results ( October 15, 2023 cutoff date ) demonstrate deep ...
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA ( anito-cel ) Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma at ASH
Arcellx Announces Continued Robust Long-Term Responses from Its CART-ddBCMA ( anito-cel ) Phase 1 Expansion ... PR ...
